Pharma Companies Are Suspending Trials In Russia - But For Practical More Than Ethical Reasons
Sanctions Block Payments For Studies
While pharma is keen to condemn Russia’s aggression, suspension of trials is for practical reasons, and not a punishment of the country’s patients.
You may also be interested in...
With the Shanghai lockdown extended, Russian vessels blacklisted and oil prices fluctuating, global freight rates are expected to increase further. Apart from a direct hit, pharma manufacturers will also feel the ripple effect as prices of raw materials like APIs increase. Scrip spoke to Indian industry to gauge the impact.
Contract research organization Cromos Pharma is looking to transfer patients and studies to west Ukraine or neigboring Poland – but maintaining data integrity in a war is against the odds.
Roche is looking to challenge AstraZeneca's dominance in PNH with its subcutaneously administered once-a-month treatment but could struggle to rival the company and Novartis’s oral therapy.